Nyrada, Inc. · ASX:NYR
Nyrada — ASX Small and Mid-Cap Conference 2021
18 slides from Nyrada's conference presentation, Sep 13, 2021
Slide 1: Presentation to ASX Small and Mid-Cap Conference
Presentation to ASX Small and Mid-Cap Conference For personal use only Sydney, 13 September 2021: Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be used by Nyrada CEO, James Bonnar at the ASX Small and Mid-Cap Conference on T
Slide 2: Forward-Looking Statements
Forward-Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: ASX Small & Mid-Cap Conference
For personal use only ASX SMALL & MID-CAP CONFERENCE James Bonnar Nyrada CEO 14 September 2021 Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board. 1
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It Although the Company believes that the expectations reflected in the forward should not be considered as an offer or invitation to subscribe for, or purchase any looking sta
Slide 5: Vision & Strategy
Vision & Strategy For personal use only To improve lives and offer hope through innovation We aim to deliver novel treatments for diseases where: There is an unmet clinical need; or Current treatments are suboptimal Commercialise early 3
Slide 6: Drug Development
Drug Development For personal use only Two lead Cholesterol-Lowering Program programs: Oral PCSK9 inhibitor to be used alone, or in combination with a statin - Key value inflection point end of Phase I Brain Injury Program Intravenous and intranasal drug to help people who sustain a traumatic brain
Slide 7: Cholesterol-Lowering Program Overview
Cholesterol-Lowering Program Overview For personal use only Cholesterol-Lowering Animation 5
Slide 8: Nyrada's Unique Solution
Nyrada’s Unique Solution For personal use only Oral Convenient Cost- PCSK9 for patient effective treatment Small molecule PCSK9 inhibitor overcomes longstanding challenge of oral treatment Can be combined with statin to deliver a first ever single pill PCSK9/statin treatment 6
Slide 9: Program Results
Program Results For personal use only ❑ NYX-PCSK9i reduced cholesterol by almost half vs. Lipitor® alone (27%) Impressive ❑ Reduced cholesterol by 65% when dosed with Lipitor® Cholesterol Lowering ❑ Equivalent cholesterol reduction to injectable PSCK9 inhibitor Praluent® Performance1 ❑ Well-tolerate
Slide 10: NYX-PCSK9i and Lipitor Reduces Cholesterol in Mouse Model
NYX-PCSK9i and Lipitor® Reduces Cholesterol in Mouse Model For personal use only In vivo study – June 2021 % Difference in plasma cholesterol versus vehicle control (p-value) Time (days) 7 14 21 28 35 NYX-PCSK9i -18% (0.066) -24% (0.002) -31% (0.001) -37% (<0.001) -46% (<0.001) Lipitor -13% (0.275)
Slide 11: Brain Injury Program Overview
Brain Injury Program Overview For personal use only Brain Injury Solution Animation 9
Slide 12: Brain Injury Problem
Brain Injury Problem For personal use only - 2.8 million traumatic brain - Treatment options limited injuries (TBI) in US (2017)1 to neurosurgery and - High mortality supportive care - Severe life-long - 4.1 million TBIs globally (2020)2 - One drug class for stroke disability (Suitable for less than
Slide 13: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 14: Program Results
Program Results For personal use only ❑ NYX-1010 showed excellent potency and blood-brain barrier Proof of Concept penetration to reach areas of the brain damaged after TBI1 Optimised ❑ NYR-BI01 more potent and drug-like compound than its predecessor Compound NYX-10101 ❑ Collaboration secured with t
Slide 15: Market Opportunity
Market Opportunity For personal use only No FDA-approved treatment for TBI is currently available In the US, UK, Europe and Japan alone, the size of the TBI market in 2020 was US$6.7 billion1 Estimated to grow at a CAGR of 5.54% 1 between 2018–2030 1 Traumatic Brain Injury, Market Insight, Epidemiol
Slide 16: Board of Directors
Board of Directors For personal use only Mr Marcus Dr Rüdiger Mr John Moore Dr Ian Dixon Christopher Cox Mr Peter Marks Frampton Weseloh Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director Nyrada operates under the
Slide 17: Key Metrics & News Flow
Key Metrics & News Flow For personal use only Market capitalisation CY 2021 CY 2022 $44M (as at 10 September 2021) Share price Cholesterol-lowering program $0.28 to enter clinic: Mid CY 2022 (as at 10 September 2021) Brain injury program CDIs free float 122,902,847 to enter clinic: 2H CY 2022 CDIs 2
Slide 18: Discover More & Follow Us
Discover More & Follow Us For personal use only info@nyrada.com www.nyrada.com @nyrada_inc @nyrada_inc Brain Injury Solution Animation Cholesterol-Lowering Animation ASX: NYR 16